Search PubMed⌕ Search

Biomedical subjects

T A Larsen

Publications and source records attributed to T A Larsen.

46 records · Page 3Linked to original sources
PubMed1984

Severity of Parkinson's disease and the dosage of bromocriptine.

In view of reports that low-dose bromocriptine (15 mg or less daily) therapy is effective in Parkinson's disease, we undertook a retrospective study of 79 patients with Parkinson's disease to evaluate factors that affect the optimal daily dose of bromocriptine in subjects whose intake of levodopa was decreased as bromocriptine was introduced. Doses of bromocriptine 15 mg or less daily were seldom therapeutic; doses of over 15 mg, up to 30 mg, were appropriate for patients with mild, early disease. Those with more severe symptoms of longer duration usually required larger doses. The optimal daily requirement of bromocriptine was correlated to the severity and duration of the illness, but not to the age of the patient.

Adult↗
PubMed1983

Essential tremor.

Explore the source record for details and available documents.

Adrenergic beta-Antagonists↗
PubMed1983

Comparison of pergolide and bromocriptine therapy in parkinsonism.

Twenty-four parkinsonian patients compared pergolide and bromocriptine therapy in a randomized double-blind, two-period crossover study. Both drugs were adjusted to an optimal balance between benefits and side effects. The mean daily dose and dose range for pergolide and bromocriptine were 3.3 mg (0.7 to 7.2) and 42.7 mg (5.8 to 87.5), respectively. Adjunctive medications, which for most patients included levodopa (plus carbidopa), were not altered during the study. A similar spectrum of clinical effects was found with both drugs and with lisuride, which was used to treat 13 of the patients in a previous study. Despite neurochemical differences in the antiparkinsonian ergots, their clinical utility is quite similar. We draw attention to hepatotoxicity and pleural reactions that may occur rarely with these drugs.

Aged↗
PubMed1983

Beta 1 versus nonselective blockade in therapy of essential tremor.

The beta 1-selective blocker metoprolol was compared to propranolol and a placebo in a double-blind crossover trial in 24 patients with essential tremor. Both beta blockers suppressed the essential tremor, but metoprolol, which caused a mean reduction of 32.0% in tremor intensity from the base-line value, was less effective than propranolol, which reduced mean tremor intensity by 41.3%. Subjective benefit for their tremor was found by 15 of the patients taking propranolol and by one taking metoprolol. The tremor frequency was not affected. No serious side effects were observed. Metoprolol may offer an alternative for those essential tremor patients who cannot tolerate propranolol.

Adult↗
PubMed1982

Atenolol vs. propranolol in essential tremor. A controlled, quantitative study.

The beta-1 selective, hydrophilic adrenoceptor blocking drug atenolol (100 mg daily) was compared to the non-selective, lipid-soluble beta-blocker propranolol (240 mg daily), and to placebo, in a double-blind cross-over study in 24 patients with essential tremor. Atenolol and propranolol caused a similar decrease in heart rate. Both beta-blockers also suppressed the tremor intensity; there was no significant difference between them, but both were significantly better than placebo. These drugs did not affect tremor frequency. Twelve of the patients preferred propranolol subjectively, one preferred atenolol and none preferred placebo. No marked side-effects were observed. It was concluded that atenolol and other cardio-selective blockers offer an alternative for patients unable to tolerate the non-selective drugs. The site of action and receptor sub-type involved have still to be determined.

Adult↗
PubMed1982

Propranolol and essential tremor: rôle of the membrane effect.

d-propranolol is almost devoid of beta-blocking effect but has the same membrane stabilizing properties as the dl-form. In order to study the importance of membrane stabilizing activity versus beta blockade in the therapeutical effect of propranolol on essential tremor, we compared d-propranolol with dl-propranolol in 24 patients in a placebo-controlled double-blind cross-over study. dl-propranolol reduced tremor intensity better than d-propranolol. The d-form did not significantly differ from placebo in its effects on tremor, although it did reduce the heart rate slightly. It is concluded that the membrane effect is not important in the therapeutic effect of propranolol in essential tremor.

Adult↗
PubMedDate not supplied

Magnetoencephalographic evaluation of children and adolescents with intractable epilepsy.

Magnetoencephalographic (MEG) discharges were recorded with multichannel superconducting quantum interference device (SQUID) gradiometers in 13 young candidates for epilepsy surgery. The sources of epileptic activity were related to generators of somatosensory and auditory evoked cortical responses and projected on magnetic resonance imaging (MRI) scans. Seven subjects had restricted or regional MEG foci, located in the frontoopercular (1), sensorimotor (3), perisylvian (1), mesiotemporal (1), or temporooccipital cortex (1). The MEG foci in the 3 patients who underwent operation agreed with the intracranial findings. Findings in the other patients emphasize the need to collect further data to define the ultimate role of MEG in preoperative evaluation of epilepsy.

Adolescent↗